Protein Forest Expands into Europe
News Jan 09, 2009
Protein Forest© announced that it has opened new business in Europe. Led by newly appointed Robert Marchmont, Ph.D. the European division will be headquartered in Newcastle upon Tyne, UK and will include office space and laboratory facilities to support sales, product demonstrations, applications development and collaborative projects with European customers.
Dr. Marchmont joins Protein Forest as European Business Director and brings with him over 25 years experience in the Life Science industry most recently with GE Healthcare. His particular focus on proteomics technologies and breadth of business expertise makes him an ideal appointment to this role.
“We are delighted to welcome Bob to the Protein Forest team and look forward to him setting up dedicated sales, a customer support team and distribution networks within Europe.” said Russell Garlick, Ph.D., President and CEO of Protein Forest. “There is growing confidence in the proteomics field applying our digital ProteomeChip (dPC™) sample preparation technology for mass spectrometry based proteomics and there are particular advantages to applying the dPC to aspects of targeted proteomics within clinical research.”
He added, “This confidence is highlighted particularly by the sustained investment we are receiving and customers’ purchases in such challenging times that exist today”.
Dr Marchmont commented, “I am delighted to be joining Protein Forest and to showcasing the benefits of our innovative product portfolio to European proteomic scientists. The Protein Forest dPC technology brings new advancements in data quality and speed to results for researchers applying mass spectrometry to their work.”
Existing 20-year-old Multiple Sclerosis Drug Effective Against Multi-resistant BacteriaNews
A widely-used and twenty-year-old medicine used to treat multiple sclerosis can also beat a type of multi-resistant bacteria for which there are currently only a few effective drugs.READ MORE
Protein "Intentionally" Terminates own Synthesis by Destabilizing Synthesis Machinery — the RibosomeNews
A research group has discovered that a protein, during its synthesis, may destabilize the structure of the ribosome and end its own synthesis prematurely, and found that this phenomenon is used for adapting the cell to its environment.READ MORE
Pre-Diabetes Discovery Marks Step Towards Precision MedicineNews
Identification of three molecules that can be used to accurately assess pre-diabetes – a key predictor of conditions such as diabetes and high blood pressure – has brought precision medicine for humans a step closer.READ MORE